Business Description
Harvard Bioscience Inc
NAICS : 334516
SIC : 3826
ISIN : US4169061052
Total Employee Number:
339Description
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.16 | |||||
Equity-to-Asset | 0.13 | |||||
Debt-to-Equity | 4.39 | |||||
Debt-to-EBITDA | 27.86 | |||||
Interest Coverage | 0.11 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -2.39 | |||||
Beneish M-Score | -2.96 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -10.7 | |||||
3-Year Book Growth Rate | -43.6 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.35 | |||||
9-Day RSI | 46.85 | |||||
14-Day RSI | 49.12 | |||||
3-1 Month Momentum % | 30.61 | |||||
6-1 Month Momentum % | 2.77 | |||||
12-1 Month Momentum % | 36.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.99 | |||||
Quick Ratio | 1.06 | |||||
Cash Ratio | 0.3 | |||||
Days Inventory | 225.16 | |||||
Days Sales Outstanding | 58.16 | |||||
Days Payable | 48.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2 | |||||
Shareholder Yield % | 1.59 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 58.42 | |||||
Operating Margin % | 0.72 | |||||
Net Margin % | -11.44 | |||||
EBITDA Margin % | 1.85 | |||||
FCF Margin % | 1.5 | |||||
OCF Margin % | 3.6 | |||||
ROE % | -71.5 | |||||
ROA % | -12.36 | |||||
ROIC % | 0.78 | |||||
3-Year ROIIC % | -10.91 | |||||
ROC (Joel Greenblatt) % | -13.05 | |||||
ROCE % | -10.97 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 71.09 | |||||
PS Ratio | 0.32 | |||||
PB Ratio | 2.66 | |||||
Price-to-Free-Cash-Flow | 20.38 | |||||
Price-to-Operating-Cash-Flow | 8.54 | |||||
EV-to-EBIT | -15.72 | |||||
EV-to-Forward-EBIT | 51.1 | |||||
EV-to-EBITDA | 40.26 | |||||
EV-to-Forward-EBITDA | 13.2 | |||||
EV-to-Revenue | 0.75 | |||||
EV-to-Forward-Revenue | 2.12 | |||||
EV-to-FCF | 49.78 | |||||
Price-to-GF-Value | 0.31 | |||||
Price-to-Projected-FCF | 0.67 | |||||
Price-to-Median-PS-Value | 0.27 | |||||
Earnings Yield (Greenblatt) % | -6.36 | |||||
FCF Yield % | 4.79 | |||||
Forward Rate of Return (Yacktman) % | -4.34 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Harvard Bioscience Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 85.531 | ||
| EPS (TTM) ($) | -2.17 | ||
| Beta | 1.8143 | ||
| 3-Year Sharpe Ratio | -0.75 | ||
| 3-Year Sortino Ratio | -0.96 | ||
| Volatility % | 75.53 | ||
| 14-Day RSI | 49.12 | ||
| 14-Day ATR ($) | 0.347425 | ||
| 20-Day SMA ($) | 6.112 | ||
| 12-1 Month Momentum % | 36.72 | ||
| 52-Week Range ($) | 3.755 - 9.4 | ||
| Shares Outstanding (Mil) | 4.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Harvard Bioscience Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Harvard Bioscience Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 116 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 115 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 08:00 | In 29 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 28 days | ||
| General meeting for 2026 | 2026-06-02 10:00 | 6.40 (+11.11%) | ||
| Benchmark (StoneX) Healthcare House Call Virtual Conference | 2026-05-28 | 5.78 (+0.61%) | ||
| Sidoti Micro Cap Conference | 2026-05-21 11:30 | 5.40 (+5.68%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 08:00 | 6.84 (-0.87%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 6.84 (-0.87%) | ||
| KeyBanc Virtual Healthcare Forum | 2026-03-17 14:15 | 5.01 (+12.58%) |
Show
Entries
Harvard Bioscience Inc Frequently Asked Questions
What is Harvard Bioscience Inc(HBIO)'s stock price today?
The current price of HBIO is $5.93. The 52 week high of HBIO is $9.40 and 52 week low is $3.76.
When is next earnings date of Harvard Bioscience Inc(HBIO)?
The next earnings date of Harvard Bioscience Inc(HBIO) is 2026-08-11 Est..
Does Harvard Bioscience Inc(HBIO) pay dividends? If so, how much?
Harvard Bioscience Inc(HBIO) does not pay dividend.
Guru Commentaries on NAS:HBIO
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Harvard Bioscience Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers